Trial Profile

An Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 to Evaluate the Long-Term Safety and Effectiveness of CIN-107

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baxdrostat (Primary)
Indications Hypertension
Focus Adverse reactions
Sponsors AstraZeneca; CinCor Pharma

Most Recent Events

17 Nov 2023 Status changed from active, no longer recruiting to completed.
22 Jun 2023 The protocol of this study has been amended as Therapeutic primary endpoints that were included in this study has been removed and trial focus of this study has now shifted to Ar only.
18 Nov 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com